Company news
Halozyme Therapeutics, Inc. news in 2024
Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
December 29, 2024
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
December 29, 2024
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
December 29, 2024
Halozyme to Present at Upcoming Investor Conferences
November 26, 2024
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
November 21, 2024
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
November 17, 2024
Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
November 13, 2024
Halozyme reports third quarter 2024 financial and operating results
October 30, 2024
Halozyme provides update on licensee co-formulation patent hearing in Europe
October 23, 2024
Halozyme to Report Third Quarter 2024 Financial and Operating Results
October 22, 2024
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
October 2, 2024
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
September 12, 2024
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
September 11, 2024
Halozyme reports second quarter 2024 financial and operating results
August 5, 2024
Halozyme to Report Second Quarter 2024 Financial and Operating Results
July 22, 2024
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
June 24, 2024
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
June 20, 2024
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
June 5, 2024
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
June 4, 2024
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 3, 2024
Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
May 20, 2024
Halozyme to Participate in Upcoming Investor Conferences
May 7, 2024
Halozyme reports first quarter 2024 financial and operating results
May 6, 2024
Mahesh Krishnan Elected to Halozyme's Board of Directors
April 24, 2024
Halozyme to Report First Quarter 2024 Financial and Operating Results
April 22, 2024
Halozyme reports fourth quarter and full year 2023 financial and operating results
February 19, 2024
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
February 7, 2024
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 28, 2024
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
January 17, 2024
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 15, 2024
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
January 15, 2024
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
January 11, 2024
Calls in 2024
- Halozyme Therapeutics (NASDAQ:HALO) Q3 2024 Earnings Call
Oct 31, 2024
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q2 2024 Earnings Call
Aug 6, 2024
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q1 2024 Earnings Call
May 7, 2024
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q4 2023 Earnings Call
Feb 20, 2024
Transcript
Decks in 2024
- Q3 2024 Earnings Presentation
Earnings · 19 slides · Oct 31, 2024
- Corporate Update (October 2024)
Corporate update · 9 slides · Oct 24, 2024
- Q2 2024 Earnings Presentation
Earnings · 18 slides · Aug 6, 2024
- Q1 2024 Earnings Presentation
Earnings · 17 slides · May 7, 2024
- Q4 2023 Earnings Presentation
Earnings · 23 slides · Feb 20, 2024
- Investor Presentation (January 2024)
Investor deck · 31 slides · Jan 17, 2024